Cholestasis

Subscribe to Selected New Research on Cholestasis

4044 relevant articles (205 outcomes, 338 trials/studies) found for this Disease

Description: Impairment of bile flow due to obstruction in small bile ducts (INTRAHEPATIC CHOLESTASIS) or obstruction in large bile ducts (EXTRAHEPATIC CHOLESTASIS).

Also Known As:

Bile Duct Obstructions; Biliary Stases; Cholestases; Duct Obstruction, Bile; Duct Obstructions, Bile; Obstruction, Bile Duct; Obstructions, Bile Duct; Stases, Biliary; Stasis, Biliary; Bile Duct Obstruction; Biliary Stasis

Relationship Network

Disease Context: Research Results

Digestive System Diseases: 29

Biliary Tract Diseases: 303

Bile Duct Diseases: 39

Cholestasis: 4044

Intrahepatic Cholestasis: 807

Extrahepatic Cholestasis: 211

Related Diseases

1.	Pruritus (Itching)
2.	Biliary Liver Cirrhosis (Primary Biliary Cirrhosis)
3.	Liver Diseases (Liver Disease)
4.	Intrahepatic Cholestasis
5.	Necrosis

Experts

1.	Roma, Marcelo G: 7 articles (06/2006 - 04/2002)
2.	Mottino, Aldo D: 6 articles (11/2007 - 04/2002)
3.	Crocenzi, Fernando A: 6 articles (06/2006 - 04/2002)
4.	Benedetti, Antonio: 5 articles (10/2007 - 10/2004)
5.	Dehpour, Ahmad Reza: 4 articles (02/2008 - 04/2002)
6.	Marzioni, Marco: 4 articles (10/2007 - 02/2006)
7.	Francis, Heather: 4 articles (07/2007 - 10/2004)
8.	Alpini, Gianfranco: 4 articles (07/2007 - 10/2004)
9.	Dehpour, Ahmad R: 4 articles (03/2007 - 10/2002)
10.	Pellegrino, José M: 4 articles (06/2006 - 04/2002)

Drugs and Biologics

Drugs and Important Biological Agents (IBA) related to Cholestasis:

1.	Ursodeoxycholic Acid (Urso)FDA LinkGeneric 01/01/2006 - "We have investigated whether maternal obstructive cholestasis during pregnancy (OCP) causes oxidative stress and apoptosis in rat placenta and whether treatment with ursodeoxycholic acid (UDCA, i.g., 60 microg/100 g b.wt./day, following complete biliary obstruction on day 14 of pregnancy) has protective effects on this organ" 03/01/2003 - "Cholestasis and liver function tests improved significantly during treatment with ursodeoxycholic acid (750 mg per day)" 12/01/1997 - "Successful therapy of persistent androgen-induced cholestasis with ursodeoxycholic acid]" 03/01/2000 - "These cases suggest that ursodeoxycholic acid may be an effective treatment for drug-associated cholestasis." 10/01/1995 - "In an uncontrolled series of three patients with cholestasis of pregnancy, ursodeoxycholic acid seemed to provide safe and effective therapy." Order ALL the reference details at left...
2.	BilirubinIBA 01/01/1997 - "The results showed a significant reduction in the measured gallbladder area in group II alcoholics, but not in patients of group I. Furthermore, three weeks of treatment with Pergoli water significantly reduced to normal total and direct bilirubin levels, the enzyme markers of biliary stasis and the subjective sensation of itch" 08/01/1999 - "The measurement of CB in blood is superior to the measurement of direct bilirubin because an abnormal concentration of direct bilirubin does not necessarily indicate the presence of cholestasis." 12/01/1980 - "In one patient, it was observed that continuous PTCD over three weeks was effective in reducing serum bilirubin by relief of cholestasis" 12/01/2006 - "Cholestasis and levels of bilirubin improved over time" 02/01/1980 - "The hepatic clearance of unconjugated radiobilirubin was normal at all times in this patient, although during cholestasis, conjugated bilirubin reflexed from the liver to the plasma and was then cleared slowly with a half life of approximately 12 hours" Order ALL the reference details at left...
3.	Rifampin (Rifampicin)FDA LinkGeneric 03/18/1989 - "Both drugs were equally effective in inducing hepatic microsomal function but rifampicin has the additional effect of reducing cholestasis" 10/22/2004 - "Consistent with these studies, the antibiotic rifampicin, a ligand for human PXR, reduces hepatic bile acid levels in cholestasis patients" 01/01/2005 - "Rifampicin inhibition of bile acid synthesis may be a protective mechanism against drug and bile acid-induced cholestasis." 07/01/1993 - "A prospective study is warranted to assess further the effect of rifampicin treatment in children with hepatic cholestasis." 09/01/1989 - "The administration of rifampicin caused cholestasis alone" Order ALL the reference details at left...
4.	Bile Acids and Salts (Bile Acids)IBA 01/01/2003 - "CONCLUSION: The results demonstrate that there is a functional adaptive downregulation of renal tubular bile acid transport enhancing renal clearance of bile acids during the early phase of an obstructive cholestasis." 03/24/1989 - "These findings indicate that altered metabolism, such as 1 beta- or 6 alpha-hydroxylation of bile acids, is enhanced in cholestasis, and that the resulting hydroxylated metabolites are eliminated in the urine." 07/01/2008 - "In conclusion, the present study clearly demonstrated that OAT3 is responsible for renal secretion of bile acids during cholestasis and that the pharmacokinetic profile of OAT3 substrates may be affected by cholestasis." 09/01/2006 - "Chronic injection of EE (2 mg/kg, s.c., for 14 days) induced cholestasis as documented by increased serum concentrations of bile acids and caused a higher incidence of body scratching compared to vehicle, thus providing an animal model to study scratching behavior secondary to cholestasis" 07/01/2006 - "Recent studies have begun to characterize the cellular and molecular mechanisms of hepatocyte injury caused by the retention of hydrophobic bile acids in cholestasis" Order ALL the reference details at left...
5.	EnzymesIBA 01/01/1982 - "Clinical and experimental studies of membrane bound enzymes in cholestasis (author's transl)]" 04/01/1979 - "The rise of the activity of the enzymes under study within the first days after operation and its normalization by the 7th to 14th days in all the studied variants of hemo- an cholestasis have been established." 01/01/1974 - "Histochemical studies of hepatic enzymes in dogs subjected to lobar bile duct obstruction." 07/01/1973 - "Histochemical study of so-called "marker enzymes of cholestasis" during extrahepatic bile duct obstruction in the rat." 12/01/2007 - "CONCLUSIONS: There is no substantial evidence that the level of oxidative enzymes in a blood sample can be an indicator of oxidative stress in pregnant women with PIH, HA or cholestasis" Order ALL the reference details at left...
6.	Biological Markers (Surrogate Marker)IBA 01/01/2001 - "Multicenter randomised controlled trials proved that the treatment is associated with a marked improvement in serum biochemical markers of cholestasis, i.e" 09/01/2006 - "Improvement in symptoms was associated with a significant improvement in biochemical markers of cholestasis" 04/01/2000 - "This therapy also causes a significant improvement of all the biochemical markers of cholestasis but has no beneficial effects on any of the symptoms or associated disorders" 05/01/2006 - "Two weeks after OLT, bile duct injury and cholestasis were assessed by light and electron microscopy, as well as through molecular and biochemical markers" 01/01/2005 - "Many of the known factors that affect hepatic biomarkers are similar to those affecting other tissue markers, while others are unique to the liver, such as those involved with cholestasis" Order ALL the reference details at left...
7.	Alkaline PhosphataseIBA 01/22/1996 - "Treatment-related decreases in alkaline phosphatase activity occurred, however, in 39-56% of the studies; serum alkaline phosphatase may be more useful as an indicator of decreased food intake (decreased activity) than of cholestasis (increased activity)" 01/01/1982 - "Studies on the mechanism of the increase in serum alkaline phosphatase activity in cholestasis: significance of the hepatic bile acid concentration for the leakage of alkaline phosphatase from rat liver." 09/01/1979 - "Clinical studies, as well as experimentally induced bile duct obstruction, have shown canine GGT increases to coincide with increases in alkaline phosphatase" 05/01/2007 - "Elevation of hepatic aminotransferase and alkaline phosphatase with cholestasis was common." 01/19/2006 - "Laboratory findings of elevated alkaline phosphatase and gamma-GT indicate the presence of cholestasis" Order ALL the reference details at left...
8.	CholesterolIBA 06/01/1986 - "Since microtubules play an important role in the intracellular transport of many materials, including cholesterol, the present study was undertaken to assess the extent to which they participate in the development of LCA-Na-induced cholestasis" 11/01/2007 - "Three outlier samples, from cholestasis patients with serum cholesterol levels >17 mmol/L, were observed in this correlation analysis" 06/01/2007 - "In addition, murine cholestasis resulted in increased hepatic cholesterol synthesis that may contribute to the higher plasma free cholesterol levels found during the early hours after BDL" 02/08/2005 - "These results demonstrate that CAR and PXR influence cholesterol metabolism and bile acid synthesis, as well as multiple detoxification pathways, and suggest their potential role as therapeutic targets for the treatment of cholestasis and lipid disorders." 06/01/2003 - "In conclusion, the critical cholestatic events in Mn-Br-induced cholestasis appear to be mediated through the synergistic effects of Mn and BR acting on synthesis and degradation of cholesterol." Order ALL the reference details at left...
9.	Taurine FDA Link 01/01/1992 - "Taurine therapy is recommended, because it might be effective for treating neonatal cholestasis." 12/01/1992 - "Although simultaneous addition of UDCA also showed slight improvement, with or without taurine pre-treatment, biliary bile-salt analysis also showed that cholestasis was markedly remitted as the excretion of taurine-conjugated UDCA was increased" 10/01/2005 - "Taurine and cholestasis associated to TPN" 05/01/2003 - "The data show that oral supplementation of taurine induces Mrp2 and Bsep expression and may prevent LPS-induced cholestasis." 05/01/2003 - "The effect of oral taurine supplementation on endotoxin-induced cholestasis was investigated in rat liver" Order ALL the reference details at left...
10.	1-phenyl-3,3-dimethyltriazene (PDT)IBA 05/01/2005 - "However, PDT leads to a significant reduction of cholestasis" 08/01/2006 - "In a randomized trial of patients with nonresectable cholangiocarcinoma, PDT prolonged survival time, improved cholestasis and quality of life considerably, and had a favorable side-effect profile" 11/01/2005 - "OBJECTIVES: Preliminary uncontrolled studies of photodynamic therapy (PDT) of bile duct cancer (BDC) have shown astonishingly good results in the reduction of cholestasis, improvement of life quality, and potential improvement of survival time" 07/01/2001 - "OBJECTIVES: Preliminary results of photodynamic therapy (PDT) of bile duct cancer have shown astonishingly good results in the reduction of cholestasis, improvement of quality of life, and even prolongation of the survival time" 03/01/2008 - "BACKGROUND & AIMS: Photodynamic therapy (PDT) for unresectable cholangiocarcinoma is associated with improvement in cholestasis, quality of life, and potentially survival" Order ALL the reference details at left...

Therapies and Procedures

1.	Parenteral Nutrition 02/01/2008 - "CONCLUSION: Cholestasis remains an important complication of parenteral nutrition, and several clinical and biochemical factors may be helpful in identifying high-risk patients." 05/01/2007 - "Although it has been more than a quarter of a century since parenteral nutrition was first introduced and its association with hepatic complications described, the precise etiology of parenteral nutrition associated cholestasis (PNAC) remains a mystery; however, our understanding of the molecular components that contribute to PNAC has improved substantially" 03/01/1999 - "Although Vit E-supplemented parenteral nutrition was effective in preventing the development of cholestasis in the 10-day group (p < 0.05), it was not effective in the 20-day group when compared with incidence of cholestasis in the parenteral nutrition-only group (p > 0.05)" 07/15/2006 - "Full remission or partial improvement of parenteral nutrition-associated cholestasis occurred in 11 of 12 children" 05/01/1985 - "We carried out a study to determine which of the liver function tests was the most sensitive and/or specific in detecting parenteral nutrition associated cholestasis" Order ALL the reference details at left...
2.	Aftercare (After-Treatment) 08/01/1999 - "One month after treatment, there was a significant improvement in the cholestasis indicating parameters in all Fasciola cases compared to the pretreatment ones" 01/01/2007 - "In rats treated once with ANIT (75 mg/kg, i.p.), liver injury with cholestasis occurred 24 h after treatment and progressed at 48 h" 01/01/2007 - "Before therapy, the hepatic cholestasis was present in 20 patients (54.05%), and after treatment in 14 patients (37.83%)" 07/01/2006 - "The distinction between these 2 diseases has prognostic implications: idiopathic cholestasis is usually reversible in early-stage HL after treatment, whereas patients who develop VBDS commonly die from their disease" 09/01/1999 - "One patient developed biochemical cholestasis the third day after treatment, but her enzyme profiles returned to normal after 2 months" Order ALL the reference details at left...
3.	Ligation 08/27/1997 - "These results suggest that UR-906 has a beneficial effect against cholestasis induced by bile duct ligation in rats and that this drug may be useful in the treatment of clinical cholestatic disorders." 01/01/1994 - "A reduced efficacy of VIP (43% of the control) without modification in its potency (ED50 = 2.2 nM) was observed in regenerating rat liver after cholestasis (bile duct ligation)" 05/01/2008 - "BACKGROUND: Although bile duct ligation (BDL) in mice is used to study cholestasis, a detailed description of this animal model is lacking" 04/01/2006 - "The results of these studies show that Egr-1 was rapidly upregulated, primarily in hepatocytes, in mice subjected to bile duct ligation, an animal model of cholestasis" 05/09/2005 - "Seven-day ligation of bile duct was used as the model to study cholestasis" Order ALL the reference details at left...
4.	Photochemotherapy (Photodynamic Therapy) 03/01/1998 - "The aim of this study was to evaluate the effect of photodynamic therapy on cholestasis, quality of life, and survival in these patients" 10/18/2006 - "Photodynamic therapy, a light therapy, is the first approach leading to an improvement of cholestasis and quality of life as well as to a prolongation of survival time" 08/17/2000 - "Preliminary data of photodynamic therapy in bile duct cancer show good results concerning reduction of cholestasis, improvement of life quality and even prolongation of survival time" 05/01/2004 - "Endoscopic procedures, such as PTC- or ERC-stenting and photodynamic therapy, are important supportive therapies which can help to maintain the bile flow and consequently improve survival and quality of life of patients with malignant bile duct obstructions." 11/01/2005 - "OBJECTIVES: Preliminary uncontrolled studies of photodynamic therapy (PDT) of bile duct cancer (BDC) have shown astonishingly good results in the reduction of cholestasis, improvement of life quality, and potential improvement of survival time" Order ALL the reference details at left...
5.	Stents 05/01/2006 - "Due to the prospective protocol of the study we were able to apply an individualized endoscopic treatment: sphincterotomy with proper relief of the bile duct obstruction (stone extraction) or sphincterotomy with large-size (10 Fr) stent placement for large-sized bile duct defects" 12/01/1998 - "Randomized trial of stent placed above and across the sphincter of Oddi in malignant bile duct obstruction." 06/01/2008 - "Complications related to placement of the stent tube occurred in 4 patients with tube occlusion or cholestasis" 02/01/2007 - "Secondary cholestasis was overcome by endoscopic dilatation and biliary stenting with stents being exchanged every 3 months" 04/21/2006 - "The catheter was removed after resolution of cholestasis and stent patency was confirmed 2 or 3 d post-procedure" Order ALL the reference details at left...

Best Treatments:
Research Summary Report
on Cholestasis

CureHunter Patient-Physician Summary Reports collect in one document all the medications ever reported in the US National Library of Medicine—1949 to the present—to be effective against your target disease. CureHunter research summary reports will vary in length from 25 to 250 pages. Analytic charts allow you and your physicians to see at a glance your medication options—including new, promising, off-label and experimental all rated for clinical efficacy.

Free Updates for 1 Year
All 205 Outcomes
Top 200 Key Drugs and Biologics
Top 50 Key Therapies and Procedures
Detailed History Charts
Full Research Reference Details
Sample PDF Report on Psoriasis >>

Price:

$24.00 & Delivery via PDF download
updates for 1 year

Research Interface

Rapidly retrieve summaries of all the evidence for any disease in seconds. Save hours of search and analysis time. CureHunter is unlike any "search engine" you have ever used. Where standard "search engines" produce lists of links, CureHunter quantifies evidence, extracts it from the literature and calculates a result you can use to immediately facilitate evidence based decision making in Real Clinical Time.

Unlimited Disease, Drug and Therapy Search
2 clicks from Disease to Drug to Evidence
Trial References
All the Positive Outcomes
Detailed Relationship Timeline Charts
Full Article Reference Details
Includes Mobile Interface Subscription
One-click to FDA Products/Patents
Request Institution License Details >>

Price:

$490.00 access via web interface
1 year subscription

Proceed to Checkout >>

Mobile Interface

Retrieve summaries of all the evidence for any disease from your Mobile Phone or PDA. Accelerate decision making in the field. Speed up your study of new drug and disease domains. Refresh your knowledge on the road.

Access from any web enabled PDA or Phone
Trial references
All the Positive Outcomes
Drug and Therapy searches
Full Article Reference Details
Try Mobile Interface >>

Price:

$45.00 access via "curehunter.com/m"
1 year subscription

Proceed to Checkout >>